Cytrellis Biosystems, Inc., a medical aesthetics company bridging the gap in skin health and restoration, has announced the commercial launch of ellacor® with Micro-Coring Technology in Australia following regulatory approval from Australia's Therapeutic Goods Administration.
The approval marks a significant international milestone for Cytrellis and ellacor® through exclusive distributor Device Consulting. Physicians across Australia will now have access to the company's groundbreaking Micro-Coring Technology - a first-of-its-kind approach that treats skin laxity and improves skin quality by removing micro-cores of skin without surgery.
Originally developed to address moderate to severe wrinkles and remove excess skin on the face, ellacor® has rapidly evolved into a versatile platform capable of treating multiple areas of the body. With this approval, physicians in Australia can perform full-body resurfacing procedures on areas including the neck, abdomen, arms, thighs, knees, and other regions affected by skin laxity.
Australia represents one of the world's most sophisticated aesthetic markets, with growing demand for non-surgical procedures that address loose, crepey skin resulting from aging, weight loss, pregnancy, and the increasing use of GLP-1 medications.
